Hostname: page-component-7b7567c8c-p67k6 Total loading time: 0 Render date: 2026-11-19T12:38:27.345Z Has data issue: false hasContentIssue false

Casuistry and the moral continuum: Evaluating animal biotechnology

Published online by Cambridge University Press:  17 May 2016

Autumn Fiester*
Affiliation:
Department of Medical Ethics and the Center for Bioethics School of Medicine University of Pennsylvania 3401 Market Street, Suite 320 Philadelphia, PA 19104-3308 fiester@mail.med.upenn.edu
Get access

Abstract

While the science of animal biotechnology is advancing at a rapid pace, the ethical discussion about the boundaries the public might want to set is at the most nascent stage. There is a tendency in the public debate for opponents to favor an all-out ban on the science, while proponents want to grant it carte blanche. I argue that a more nuanced position on animal biotechnology considers individual projects to be located on a moral continuum, where some are clearly morally justified, others morally impermissible, and some lie in the ethical gray-zone. To begin to define this continuum, we use the bioethical method of casuistry to analyze one case at the end of moral permissibility, and we contrast it with a case that is located at the opposite end of the moral spectrum. I advocate this approach to assessing the moral merit of biotechnology projects because of its attention to the details of individual cases — the protocols, ends, and methods — on which an accurate moral judgment necessarily rests.

Information

Type
Research Article
Copyright
Copyright © Association for Politics and the Life Sciences 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable